AIM (AIM ImmunoTech) LT-Debt-to-Total-Asset: 0.04 (As of Mar. 2026)

What is AIM ImmunoTech LT-Debt-to-Total-Asset?

AIM ImmunoTech AIM -5.09% 33 LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AIM ImmunoTech's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.04.

AIM ImmunoTech's long-term debt to total assets ratio declined from Mar. 2025 (0.05) to Mar. 2026 (0.04). It may suggest that AIM ImmunoTech is progressively becoming less dependent on debt to grow their business.

AIM ImmunoTech (AMEX:AIM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AIM ImmunoTech LT-Debt-to-Total-Asset Related Terms

AIM ImmunoTech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech LT-Debt-to-Total-Asset Chart

AIM ImmunoTech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.02

0.03

0.05

0.19

AIM ImmunoTech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.07	0.04	0.19	0.04

33GF Score

AIM ImmunoTech Inc AIM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

AIM ImmunoTech LT-Debt-to-Total-Asset Calculation

AIM ImmunoTech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1.097	/	5.782
	=	0.19

AIM ImmunoTech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.315	/	8.585
	=	0.04

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.04 mean?

AIM ImmunoTech (AIM) has a LT-Debt-to-Total-Asset of 0.04 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on AIM ImmunoTech and its competitors.

Is AIM ImmunoTech's LT-Debt-to-Total-Asset too high?

AIM ImmunoTech's current LT-Debt-to-Total-Asset is 0.04. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does AIM ImmunoTech's LT-Debt-to-Total-Asset compare to RVPH and BOLT?

AIM ImmunoTech's LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is AIM ImmunoTech stock overvalued right now?

Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.30 — trading 89% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.30 is trading 89% below its estimated GF Value™ of $2.69. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

LT-Debt-to-Total-Asset: 0.04
GF Value™: $2.69 vs. price of $0.30 (89% below fair value)
GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Industry Healthcare Biotechnology

Comparable Companies RVPH BOLT ERNA PMCB SYBX BRTX ASBP CVKD JSPR CURX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0A4Y:UK

Address 2117 SW Highway 484, Ocala, FL, USA, 34473

Website https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

33GF Score

Get the complete analysis for AIM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30

Price

$2.69

GF Value

View AIM Analysis

See LT-Debt-to-Total-Asset data for all stocks →